stacking retatrutide with tirzepatide Retatrutide, Tirzepatide, and AOD 9604 for Weight Loss Retatrutide vs Tirzepatide: Which Peptide
Description
Brookfield Asset Management is now negotiating with Santee Cooper to buy a majority stake in the unfinished units for $2.7 billion.
Same medication
Insurance is not required, and HSA/FSA accounts are eligible
In a large phase 3 obesity trial (ACHIEVE-1), orforglipron at daily doses of 3, 12 and 36 mg caused approximately: Diarrhoea: 1926% of participants (vs 9% on placebo) Nausea: 1318% (vs 2% on placebo) Constipation: 817% (vs 4% on placebo) Vomiting: 514% (vs 1% on placebo) Across multiple studies, 617% of people stopped treatment because of side effects, mostly gut-related symptoms
